Despite thehigh level of interest in KRAS as a therapeutic target,so far only covalent inhibitors targeting the G12C allele have beenclinically approved., However, these agents are onlyeffective for a small percentage of KRAS-driven cancers, and so thereremains a need for clinically proven therapeutics that can addressother, and ideally multiple, oncogenic KRAS alleles. Here, KRAS is linked to cancer.